Stiripentol's Primary Mechanism on GABA
Stiripentol enhances GABAergic inhibition in the brain by acting as a positive allosteric modulator of GABAA receptors. It binds to a distinct site on these receptors, increasing their affinity for GABA—the main inhibitory neurotransmitter—and prolonging channel opening. This boosts chloride influx, hyperpolarizing neurons and reducing seizure excitability.[1]
How This Supports Epilepsy Therapy
In Dravet syndrome, where loss-of-function SCN1A mutations impair GABA-mediated inhibition, stiripentol restores balance. Clinical trials show it reduces seizure frequency by 50-70% when added to clobazam and valproate, partly because it inhibits clobazam's metabolism, raising its active metabolite (N-desmethylclobazam) levels for amplified GABA effects.[2][3]
Differences from Direct GABA Agonists
Unlike benzodiazepines (e.g., clonazepam), which bind the orthosteric GABA site and risk tolerance, stiripentol's allosteric action avoids rapid desensitization. It also inhibits CYP enzymes (2C19, 3A4), indirectly potentiating other GABAergic drugs without strong intrinsic agonism at low doses.[1]
Impact on GABA's Broader Therapeutic Role
Stiripentol doesn't alter GABA synthesis or release but amplifies its postsynaptic effects, making GABA therapy more effective in refractory epilepsies. This limits its use to GABA-deficient states like Dravet, not generalized epilepsies where other mechanisms dominate.[3]
Potential Risks and Limitations
High doses (>50 mg/kg) may cause sedation or ataxia from excessive GABA enhancement. It doesn't cross-correct GABA deficits in all genetic epilepsies, and long-term data on cognitive effects remain limited.[2]
[1]: Chiron C, et al. Stiripentol: pharmacology and clinical trial evidence in epilepsy. CNS Drugs. 2018.
[2]: FDA Label: Diacomit (stiripentol)
[3]: Dravet Syndrome Foundation: Stiripentol Overview